Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (5): 790-796    DOI: 10.31083/j.ejgo.2020.05.2158
Original Research Previous articles | Next articles
USP22 promotes the expression of GLUT1 and HK2 to facilitate growth and glycolysis in cervical cancer cells
Juan Xu1, Qingqing Tan1, *(), Ting Li2
1Department of Gynecological Oncology, Changzhou Maternal and Child Health Hospital affiliated to Nanjing Medical University, Changzhou City, Jiangsu Province, 213001, P. R. China
2Department of Pathology, Changzhou Maternal and Child Health Hospital affiliated to Nanjing Medical University, Changzhou City, Jiangsu Province, 213001, P. R. China
Download:  PDF(3288KB)  ( 124 ) Full text   ( 5 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Background: Cervical cancer is one of the most aggressive cancers in women, of which the pathogenesis should be further investigated to improve the prognosis. Objectives: The goal of this study is to investigate the role of ubiquitin-specific peptidase 22 (USP22) in cervical cancer and reveal its involvement in the signaling pathway. Results: Upregulation of USP22 was observed in cervical cancer tissues and cell lines. Cell proliferation, lactate production, glucose uptake and lactate dehydrogenase (LDH) activity was increased by overexpression of USP22 and decreased by suppression of USP22. The protein expression levels of Forkhead Box M1 (FoxM1), glucose transporter 1 (GLUT1) and hexokinase-2 (HK2) were upregulated by overexpression of USP22 and downregulated by suppression of USP22. Co-transfection of shUSP22 and FoxM1 attenuated the inhibitory effects of shUSP22 on the growth and glycolysis of cervical cancer cells. Conclusion: upregulation of USP22 in cervical cancer could promote cell proliferation and glycolysis through mediating FoxM1, indicating that USP22 and FoxM1 could be therapeutic targets in cervical cancer.
Key words:  USP22      GLUT1      HK2      Glycolysis      Cervical cancer cells     
Submitted:  22 October 2019      Accepted:  13 May 2019      Published:  15 October 2020     
*Corresponding Author(s):  QINGQING TAN     E-mail:  quyx78B@163.com

Cite this article: 

Juan Xu, Qingqing Tan, Ting Li. USP22 promotes the expression of GLUT1 and HK2 to facilitate growth and glycolysis in cervical cancer cells. European Journal of Gynaecological Oncology, 2020, 41(5): 790-796.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.05.2158     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I5/790

No related articles found!
[1] Eli M. Roth, Michael H. Davidson. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 31 -46 .
[2] B. Soltész, J. Lukács, A. Penyige, R. Póka, B. Nagy. Determination of miR-193b rs30236 single nucleotide polymorphism in ovarian cancer patients[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 547 -550 .
[3] Y. Li, C. Li, N. Li, L. Jiang, W. Yang, Y. Wang, B. Wu, C. Shi, Z. Zhu. RNAi silenced NUP88 gene suppresses growth and invasiveness of human breast cancer cell line MCF-7[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 634 -639 .
[4] M. Pakiž, L. Lukman, N. Kozar. Patients' and physicians' expectations differ significantly during the follow-up period after completion of primary treatment of gynecological or breast cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 781 -786 .
[5] T. Tomimatsu, S. Mabuchi, T. Tsuboyama, Y. Hori, S. Sekine, T. Kimura. Malignant transformation of uterine leiomyoma: suggested by clinical, imaging, histological, and genetic findings[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 879 -882 .
[6] Z. Protrka, P. Arsenijevic, N. Jovic, S. Zivanovic, J. Djuric, A. Dimitrijevic. A case of uterine torsion in term pregnancy associated with placental abruption and intrauterine fetal demise[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(2): 287 -289 .
[7] T. Ueno, H. Yabushita, K. Iwasaki, A. Wakatsuki. Role of adiponectin and leptin in non-diabetic, non-obese patients with endometrial cancer[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 199 -204 .
[8] P. Pimsi, W. Santimaleeworagun, S. Therasakvichya, N. Saengsukkasemsak, A. Laocharoenkeat. The incidence and risk factors of severe neutropenia and febrile neutropenia due to chemotherapy among gynecologic cancer patients in Thailand[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 242 -246 .
[9] F. Lai-Tiong. Dermatomyositis revealing a 18-year breast cancer recurrence[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 292 -293 .
[10] M.F. Benoit, K.A. O'Hanlan, M.S. Sten, C.L. Kosnik, D.M. Struck, M.S. O'Holleran, J. Cuff, D.M. Halliday, E.A. Kent. Incidental appendectomy at the time of gynecologic surgery[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 386 -389 .